Yingkai Li

Journal Article Muscle Nerve · October 2025 INTRODUCTION/AIMS: Patients with myasthenia gravis (MG) often receive immunosuppressive treatments. While approved COVID-19 vaccines effectively prevent severe infections, the impact of vaccination among immunocompromised MG patients remains unclear. This ... Full text Link to item Cite

Chronic Inflammatory Demyelinating Polyneuropathy: How Pathophysiology Can Guide Treatment.

Journal Article Muscle Nerve · August 2025 Chronic inflammatory demyelinating polyneuropathy (CIDP) is an autoimmune demyelinating neuropathy that is most commonly characterized clinically by progressive proximal and distal weakness affecting the upper and lower extremities, sensory loss, and reduc ... Full text Link to item Cite

Serum fibrinogen is not elevated in patients with myasthenia gravis.

Journal Article Sci Rep · April 15, 2025 Myasthenia gravis (MG) is an autoimmune, autoantibody-mediated disease characterized by fatigable weakness of skeletal muscles. MG is a heterogeneous disease that currently lacks a robust biomarker for diagnosing all subtypes. Residual serum fibrinogen was ... Full text Open Access Link to item Cite

Pathogenic Th17 cells are a potential therapeutic target for tacrolimus in AChR-myasthenia gravis patients.

Journal Article J Neuroimmunol · November 15, 2024 In our study, we investigated the impact of tacrolimus (TAC) on CD4+ T cell subsets in 41 AChR-MG patients over 12 weeks. Twenty-seven patients were classified as the response group (RG) (improved myasthenia gravis composite scores ≥3), while 14 were non-r ... Full text Open Access Link to item Cite

Combined Use of Magnetization Transfer Ratio and T2-Mapping to Evaluate Extraocular Muscle Pathophysiology in Myasthenia Gravis with Ophthalmoparesis

Journal Article International Journal of Medical Sciences · October 28, 2024 Full text Open Access Cite

Longitudinal changes of motor cortex function during motor recovery after stroke

Journal Article Topics in Stroke Rehabilitation · May 19, 2023 Full text Cite

Knowledge and perceptions of the COVID-19 pandemic among patients with myasthenia gravis: follow up survey

Conference RRNMF Neuromuscular Journal · February 7, 2023 Introduction We previously conducted a survey study in April 2020 at the beginning of the SARS-CoV-2 (COVID-19) pandemic to understand how it affected patients with myasthenia gravis (MG). Since then, significant advances have occurred in th ... Full text Open Access Cite

Leflunomide combined with low-dose prednisone inhibits proinflammatory T cells responses in myasthenia gravis patients

Journal Article Frontiers in Neurology · September 9, 2022 We previously found that leflunomide combined with low-dose prednisone rapidly improved the clinical symptoms of myasthenia gravis (MG), but we had not investigated the mechanism of this phenomenon. This study documents the effect of leflunomide co ... Full text Cite

The clinical need for clustered AChR cell-based assay testing of seronegative MG.

Journal Article J Neuroimmunol · June 15, 2022 Trial eligibility in myasthenia gravis (MG) remains largely dependent on a positive autoantibody serostatus. This significantly hinders seronegative MG (SNMG) patients from receiving potentially beneficial new treatments. In a subset of SNMG patients, acet ... Full text Open Access Link to item Cite

Cellular changes in eculizumab early responders with generalized myasthenia gravis.

Journal Article Clin Immunol · October 2021 Eculizumab (ECU), a C5 complement inhibitor, is approved to treat acetylcholine receptor autoantibody positive generalized myasthenia gravis (AChR MG). The clinical effect of ECU relies on inhibition of the terminal complement complex; however, the effect ... Full text Link to item Cite

Normative dataset for plasma cytokines in healthy human adults.

Journal Article Data Brief · April 2021 We determined normative data for plasma cytokines established from a cohort of 126 carefully screened healthy adults aged 18 to 64 years. Participants were enrolled to ensure an even age and sex distribution and to include at least 30% non-Caucasians. Plas ... Full text Open Access Link to item Cite

Knowledge and perceptions of the COVID-19 pandemic among patients with myasthenia gravis.

Journal Article Muscle Nerve · March 2021 BACKGROUND: Patients with myasthenia gravis (MG) may be particularly vulnerable during the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic due to risk of worsening disease during infection, potential adverse impacts of coronavirus dis ... Full text Link to item Cite

COVID-19-associated risks and effects in myasthenia gravis (CARE-MG).

Journal Article Lancet Neurol · December 2020 Full text Link to item Cite

Circulating Th1/17 cells serve as a biomarker of disease severity and a target for early intervention in AChR-MG patients

Journal Article Clinical Immunology · September 2020 Full text Cite

Imbalance in T follicular helper cells producing IL-17 promotes pro-inflammatory responses in MuSK antibody positive myasthenia gravis.

Journal Article J Neuroimmunol · August 15, 2020 A detailed understanding of the role of Tfh cells in MuSK-antibody positive myasthenia gravis (MuSK-MG) is lacking. We characterized phenotype and function of Tfh cells in MuSK-MG patients and controls. We found similar overall Tfh and follicular regulator ... Full text Link to item Cite

Imbalance of the two main circulating dendritic cell subsets in patients with myasthenia gravis

Journal Article Clinical Immunology · August 2019 Full text Cite

Tacrolimus inhibits Th1 and Th17 responses in MuSK-antibody positive myasthenia gravis patients.

Journal Article Exp Neurol · February 2019 Muscle specific tyrosine kinase antibody positive myasthenia gravis (MuSK- MG) is characterized by autoantibodies against the MuSK protein of the neuromuscular junction resulting in weakness of bulbar and proximal muscles. We previously demonstrated that p ... Full text Link to item Cite